Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05489601 · ClinicalTrials.gov registry record

Non-intrusive Detection of Temporary Neurologic Impairment by Opioids

A clinical trial of Neurologic Impairment by Opioids, sponsored by Zxerex Corporation.

Completed
Registry status
17
Enrollment target
1
Study location

NCT05489601: Completed study of Neurologic Impairment by Opioids, sponsored by Zxerex Corporation.

NCT05489601 is a study of Neurologic Impairment by Opioids that has completed, run by Zxerex Corporation. The registered enrollment target is 17 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05489601, a study of Neurologic Impairment by Opioids, has completed, sponsored by Zxerex Corporation.

COMPLETED
Registry status
17 participants
Enrollment target
1
Study location

Study Summary

The investigators aim to prove the feasibility of a non-invasive means to identify temporary neurological impairment resulting from the use of a commonly prescribed opioid by identifying an oculomotor biosignature associated with temporary neurologic impairment in pain-free opioid-naïve subjects, and to initiate the development of such a signature. The investigators also sought to establish the presence of a dose-dependent biosignature for opioid impairment.

Primary Outcome

Eye position over time is recorded and tracked using a specialized eye-tracking camera system during a battery of visual tests under control and oxycodone challenge conditions. This data is converted to a velocity measure as millimeters per second (mm/second) and then converted to an angular velocity as degrees of visual angle per second (dva/second).

Interventions

  • DRUG Oxycodone

Study Locations (1)

Arizona

  • Mayo Clinic - Scottsdale

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2020-02-28
Est. Completion 2022-03-29
Zxerex Corporation

1 total trials

What the finished NCT05489601 record still lists

NCT05489601 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.

The record links to 1 condition, with Neurologic Impairment by Opioids appearing as the primary indexed condition, and to 1 intervention - of which Oxycodone is the first listed.

NCT05489601 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT05489601 about?

NCT05489601 is a clinical study titled "Non-intrusive Detection of Temporary Neurologic Impairment by Opioids". The investigators aim to prove the feasibility of a non-invasive means to identify temporary neurological impairment resulting from the use of a commonly prescribed opioid by identifying an oculomotor biosignature associated with temporary neurologic impairment in pain-free opioid-naïve subjects, a...

What is the current status of trial NCT05489601?

This trial is currently completed. The enrollment target is 17 participants. The study started on 2020-02-28. Estimated completion is 2022-03-29.

What conditions does trial NCT05489601 study?

This clinical trial studies the following conditions: Neurologic Impairment by Opioids.

What interventions are being tested in trial NCT05489601?

The interventions under investigation include: Oxycodone (DRUG).

Who is sponsoring clinical trial NCT05489601?

This trial is sponsored by Zxerex Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05489601 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05489601, the US trial registry maintained by the National Library of Medicine. NCT05489601 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.